As oncology therapies continue to deliver deeper responses, improved survival, and earlier intervention opportunities, sponsors face increasing pressure to adapt their clinical development strategies. New treatment modalities, biomarker-driven approaches, and evolving regulatory expectations are impacting how trials are designed, executed, and scaled.

Learn how forward-looking trial design can help you balance scientific innovation with feasibility, regulatory requirements, and patient-centered execution in this article from our experts, that explores key insights from ASCO 2026.